Reciprocal relationship between expression of hypoxia inducible factor 1α (HIF-1α) and the pro-apoptotic protein Bid in ex vivo colorectal cancer

British Journal of Cancer

Volumn 99, Issue 3, 2008, Pages 459-463

  Seenath, M M ^a,b   Roberts, D ^a   Cawthorne, C ^a   Saunders, M P ^b   Armstrong, G R ^c   O'Dwyer, S T ^b   Stratford, I J ^d   Dive, C ^a,d   Renehan, A G ^a,b,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bid; Colorectal cancer; HIF 1 ; Tumour hypoxia

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BID;

ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; CANCER CELL; CELL SUBPOPULATION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECTUM CARCINOMA;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; COLORECTAL NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY;

EID: 48349143485     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604474     Document Type: Article

References (19)

1. Andersen MH, Becker JC, Straten P (2005) Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 4: 399-409
2. Bibi R, Pranesh N, Saunders MP, Wilson MS, O'Dwyer ST, Stern PL, Renehan AG (2006) A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. Br J Cancer 10: 10
3. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C (2004) Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24: 2875-2889
4. Greijer AE, van der Wall E (2004) The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57: 1009-1014
5. Hussein D, Estlin EJ, Dive C, Makin GW (2006) Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 5: 2241-2250
6. Letai AG (2008) Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 8: 121-132
7. Makin G, Dive C (2003) Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. Trends Mol Med 9: 251-255
8. Melillo G (2007) Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26: 341-352
9. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG, Borea PA (2007) Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol 72: 162-172
10. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST (2000) Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 83: 1344-1350
11. Rhodes A, Jasani B, Balaton AJ, Miller KD (2000) Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 53: 292-301
12. Saunders M, Iveson T (2006) Management of advanced colorectal cancer: state of the art. Br J Cancer 95: 131-138
13. Saunders MP, Patterson AV, Stratford IJ (2002) Programming of radiotherapy and sensitization. In Oxford Textbook of Oncology, Souhami RL, Tannock I, Hohenberger P, Horiot J-C (eds) 2nd edn, Vol. 1, pp 459-474. Oxford: Oxford University Press
14. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS (2002) BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4: 842-849
15. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732
16. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29: 297-307
17. Welsh SJ, Powis G (2003) Hypoxia inducible factor as a cancer drug target. Curr Cancer Drug Targets 3: 391-405
18. Wilson JW, Nostro MC, Balzi M, Faraoni P, Cianchi F, Becciolini A, Potten CS (2000) Bcl-w expression in colorectal adenocarcinoma. Br J Cancer 82: 178-185
19. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083